KOBIOLABS Venture Capital
3 known investors
Find your way into KOBIOLABS Venture Capital
Kobiolabs (고바이오랩) develops microbiome-based drugs using its Smartiome platform, which applies AI-driven microbiome multi-omics analysis and a microbial library for drug discovery. The company focuses on immune, metabolic, and brain/neurological diseases, and uses a biofoundry-based microbe drug delivery system (mDDS).
Also known as KoBioLabs · 고바이오랩
Investors · 3
Company profile
researched Aug 2026KOBIOLABS (고바이오랩) is a South Korean drug developer focused on microbiome-based therapeutics. The company frames its work around the human microbiome — the collection of microorganisms inhabiting a given environment, with roughly 38 trillion microbes described as present in the human body — and its interaction with human immunity, metabolism, neurotransmission and hormonal regulation as a route to treating disease.
The company organizes its therapeutic programs into four disclosed pipeline areas: immunity, metabolism, immuno-oncology, and CNS/pain, and identifies immune, metabolic and brain diseases as its priority indication groups. Its website also maintains investor relations material including stock information and IR data, alongside publications and recruiting sections.
Business model
Development of novel microbiome-based drug candidates across multiple therapeutic areas, supported by a proprietary discovery platform and internal R&D operations.
Latest developments
In March 2026 the company joined a national project led by Kakao Healthcare to develop and build a hyperscale AI healthcare service for children and adolescents. It announced participation in the IHMC 2026 Seoul international academic conference (May 2026) and in BIO USA 2026, where it planned to present its pipeline to global pharmaceutical and biotech companies and pursue partnering opportunities.
▸Full profile — market position, technology, geography
Market position
Positions itself as a leading developer of innovative microbiome therapeutics.
Technology
The company's core platform, Smartiome (with a stated Smartiome 2.0 version), is described as a reverse-translational ("Human Data to Human Drug") drug discovery platform combining AI-based microbiome multi-omics analysis with a microbial library. For its pipeline programs the company applies a biofoundry-enabled Microbe-Based Drug Delivery System (mDDS).
Geography
Headquartered in Seoul, South Korea, at Building 220 of the Seoul National University research complex in Gwanak-gu, with an R&D center at Korea Bio Park, Building C, in Bundang-gu, Seongnam-si, Gyeonggi-do.
Compiled by commissioned research from 2 cited public sources — announcements, filings, and press listed under research sources below.
Timeline · 3
launches, deals, and filingsThe company announced participation in BIO USA 2026 to introduce its pipeline to global pharmaceutical and biotech companies and explore global partnership opportunities.
The company announced it would take part in the IHMC 2026 Seoul international academic conference to share microbiome drug development results and strengthen global collaboration networks.
KOBIOLABS announced participation in a government-funded project organized by Kakao Healthcare to develop and build a hyperscale artificial intelligence healthcare service for children and adolescents.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 2
primary sources listed
- KOBIOLABS Venture Capitalkobiolabs.com · web
2 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does KOBIOLABS Venture Capital do?
- Korean biotech developing microbiome-based therapeutics for immune, metabolic, oncologic and neurological diseases.
- Who are KOBIOLABS Venture Capital's investors?
- KOBIOLABS Venture Capital's investors include Aju IB Invesment Corporation, Atinum Investment Co. Ltd., IMM Investment Japan.